Journal for ImmunoTherapy of Cancer Receives First Impact Factor

June 26, 2018

MILWAUKEE – Journal for ImmunoTherapy of Cancer (JITC), the open access, peer-reviewed online journal of the Society for Immunotherapy of Cancer (SITC), received its first impact factor of 8.374 today.

The impact factor, as published in the annual Journal Citation Reports (JCR), is a calculation determined on the number of 2017 citations accumulated for JITC manuscripts published in 2015 and 2016. Launched in 2013, JITC publishes original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy, from basic research to clinical applications.

Authors frequently reference a journal’s impact factor to gauge its credibility and stature and also predict the visibility of published manuscripts.

“This first JITC impact factor is a tremendous leap forward for our journal,” said JITC Editor-in-Chief Pedro J. Romero, MD. “In the five years since SITC launched its online publication, the profile of JITC, and the respect it has within the field, has increased by the day. Today’s announcement would not have been possible without the superb dedication of my colleagues serving on the JITC Editorial Board, and to the researchers who chose JITC as the venue for their manuscript.”

Interest in JITC among authors is on the rise. Journal article submissions in 2018 are 65 percent higher than last year. Previously operating on a standard monthly publication cycle, JITC has recently transitioned to a continuous publishing model where articles are posted within 15 days of acceptance.

“Today’s very exciting impact factor announcement places JITC in the top 8 percent of all journals published in the categories of oncology and immunology,” said SITC President Lisa H. Butterfield, PhD. “Under JITC founding Editor-in-Chief Dr. Romero’s leadership, vision and guidance, JITC has become one of the pre-eminent publications for cancer immunotherapy-related research, guidelines, consensus statements, reviews and more. SITC’s commitment to JITC as it’s open access society journal ensures that important, timely data is freely available to guide and inform the scientific community.”

JITC publishes manuscripts among eight dedicated sections: Basic Tumor Immunology; Case Reports; Clinical Trials Monitor; Clinical/Translation Cancer Immunotherapy; Commentary/Editorials; Guidelines and Consensus Statements; Immunotherapy Biomarkers; and Reviews. Each section is edited by a prominent and leading immuno-oncology expert. The journal is indexed in six major indexing sources, including PubMed, PubMed Central, MEDLINE, the Directory of Open Access journals, Scopus, and Clarivate Analytics' Science Citation Index Expanded (SCIE).

JITC is published online by BioMed Central Ltd., part of Springer Nature. As a benefit to its members, one article per SITC member is eligible for waived article processing charges through 2018 – a value of $2,400. Learn more about becoming a SITC member.

About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a non-profit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at and follow us on TwitterLinkedInFacebook and YouTube.

About JITC
Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer reviewed journal of the Society for Immunotherapy of Cancer. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy, on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at, make JITC the leading forum for tumor immunology and cancer immunotherapy research.

# # #


Media Contact

Julia Schultz, Director of Communications
(414) 271-2456